{"title":"阿斯利康斥资2.4亿美元收购Moderna Therapeutics mRNA技术","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I4.1918","DOIUrl":null,"url":null,"abstract":"AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"14 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I4.1918\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I4.1918\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I4.1918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AstraZeneca Places US$240 M Bet on Moderna Therapeutics’ mRNA Technology
AstraZeneca has signed an option-based deal with start-up Moderna Therapeutics to discover, develop and commercialise up to 40 messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Moderna will receive US$240 M upfront, which ranks as one of the largest initial payments ever disclosed for a discovery or preclinical-stage partnering deal. News of the collaboration came on the same day that AstraZeneca outlined a new strategy to revive growth that involves a significant overhaul of its R&D operations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
